Beta Fulltext view is in preview — article structure may vary. Browse all articles
Contents
Advances in Pharmacology & Clinical Trials Research Article 13 min read

The Role of Pharmacovigilance in Investigational New Drug (IND) Clinical Trials

Mohammad Nadeem Khan
ISSN: 2474-9214  10.23880/apct-16000233  Received: February 20, 2024  Published: March 04, 2024
 — views
 28 references
 1 table
PDF
Keywords
Pharmacovigilance Clinical Trials Safety Efficacy Data Monitoring Adverse Drug Reaction
Abstract

The total number of clinical trials registered so far across India was 63,174. Clinical trials from India accounted for only 8.7% of the total number of trials conducted, while clinical trials from the US accounted for 47% of the total number of trials registered, followed by 24% from the EU and 13.1% from Japan. We can increase the number of clinical trials by ensuring the role of pharmacovigilance in investigational new drug (IND) clinical trials in ensuring safety, efficacy and ethical conduct of pharmaceutical research. As pharmaceutical companies advance novel compounds through clinical development, pharmacovigilance serves as a comprehensive system for the detection, assessment, and mitigation of potential risks associated with investigational drugs. This perspective review explores the multifaceted role of pharmacovigilance in IND clinical trials, emphasizing its significance in safeguarding trial participants and contributing to the overall success of drug development programs. Underscores the critical role of pharmacovigilance in investigational new drug clinical trials From pre-trial planning to post-marketing surveillance, pharmacovigilance is integral in maintaining the safety, integrity, and ethical conduct of clinical research. As an essential component of the drug development process, pharmacovigilance contributes to the overarching goal of delivering safe and efficacious treatments to patients and can be increase the clinical trial participation globally.

Introduction

Asia, contributing to nearly 60% of the world population, started playing a significant role in clinical research after the globalization of clinical trials. This globalization has led to Perspective increased attention and participation from Asian countries in the clinical research arena. The total number of clinical trials registered Indian council of medical research (ICMR)) for till date was 63,174.Clinical trials from India constituted only 8.3% of the total number of trials [1]. The United States had the highest representation with 47%, followed by the European Union (EU) with 18%, and Japan with 11%. India, China, and Japan showed an increase in the number of trials registered from 2007 to 2023. Specifically, India had a 6.7% increase, China had a 9.1% increase, and Japan had a 13.1% increase during this period [2]. In contrast, India has been an attractive location for clinical trials due to a large and diverse patient population, experienced investigators, and competitive costs. Pharmaceutical and biotech companies from around the world have conducted trials in India. India’s regulatory environment for clinical trials has undergone changes to enhance patient safety and data integrity [3]. The Central Drugs Standard Control Organization (CDSCO) has implemented guidelines and amendments to streamline the approval process and ensure ethical conduct. Efforts have been made to improve patient recruitment in clinical trials and to ensure the inclusion of diverse populations to enhance the generalizability of study results [2]. The integration of digital technologies, electronic data capture (EDC), and mobile health (mHealth) solutions has been increasing to streamline data collection and monitoring processes in clinical trials [3]. There has been a growing emphasis on public awareness and education regarding clinical trials. Ethical considerations and informed consent processes have become more robust. The COVID-19 pandemic has had implications for ongoing and planned clinical trials worldwide, including in India. Some trials were temporarily halted or modified to adapt to the challenges posed by the pandemic. Increased collaboration between Indian research institutions, pharmaceutical companies, and international organizations has been observed to strengthen the clinical trial ecosystem. There has been a global push for increased transparency in clinical trial data. Initiatives such as the Clinical Trials Registry - India (CTRI) aim to enhance transparency and accessibility of trial information [4].

Clinical trials are conducted to assess the safety and efficacy of chemical or biological compounds, particularly their impact on specific markers or known disease processes. These trials are essential for gathering data on a drug’s performance in humans [5]. Pharmacovigilance is emphasized as a critical component that operates in tandem with clinical trials. Its primary role is to collect, assess, and monitor data on the risks and benefits of drugs. This information is vital in determining whether the benefits of a drug outweigh its potential risks. The overarching goal is to conduct a thorough risk-benefit assessment. If the benefits of a drug are found to exceed its risks, drug manufacturers take steps to seek regulatory approval for marketing the new drug. Clinical trials are closely monitored by investigators and the pharmaceutical companies involved in drug development. However, an additional layer of independent review by drug safety firms is highlighted, emphasizing the importance of unbiased evaluation. The statement underscores the global responsibility of drug developers, manufacturers, pharmaceutical systems, and investigators [6]. It emphasizes the commitment to providing the best possible care for patients and consumers worldwide. Pharmacovigilance is presented as a mechanism that adds an extra layer of security to ensure that only safe and effective products reach patients. This aligns with the broader goal of maintaining high standards of healthcare globally [7]. The synergy between clinical trials and pharmacovigilance is crucial in the drug development process. The careful assessment of risks and benefits, along with the monitoring and oversight mechanisms, aims to deliver safe and effective pharmaceutical products to patients worldwide. This integrated approach reflects the commitment of stakeholders to global healthcare standards.

Pharmacovigilance Utility

Pharmacovigilance (PV) plays a vital role in clinical research by focusing on the monitoring, detection, assessment, understanding, and prevention of adverse effects or any other drug-related problems. PV contributes to the pre-approval phase by actively monitoring and managing risks during clinical trials. It involves the systematic collection and analysis of safety data to ensure participant well-being [8]. After regulatory approval, PV extends its role to post-marketing surveillance. This phase involves monitoring the safety and effectiveness of medications in real-world settings. It helps identify rare or long-term adverse effects that may not have been evident during pre-approval studies. Pharmacovigilance professionals continuously monitor adverse events during clinical trials. This includes the collection, assessment, and reporting of any unexpected or serious side effects to regulatory authorities. Pharmacovigilance teams use various methods, such as statistical analysis and data mining, to detect signals that may indicate potential safety concerns or patterns of adverse events. Early detection allows for timely investigation and appropriate risk mitigation [9]. Ensuring accurate and timely safety reporting is a key responsibility of pharmacovigilance in clinical research. This involves preparing and submitting safety reports to regulatory agencies as per regulatory requirements. Pharmacovigilance utilizes drug registries, spontaneous reporting systems, and electronic health records to enhance surveillance capabilities [10]. These systems provide valuable real-world data on drug safety and usage. Effective communication about drug safety is crucial. Pharmacovigilance professionals contribute to educating healthcare professionals, study participants, and the public about potential risks, benefits, and the importance of reporting adverse events. Based on safety data, pharmacovigilance may recommend or implement risk minimization strategies during clinical trials [11]. These strategies aim to reduce potential risks and enhance patient safety. Pharmacovigilance activities must adhere to regulatory requirements and guidelines. This includes the submission of periodic safety reports and adherence to good pharmacovigilance practices. Collaboration with clinical investigators, regulatory agencies, and other stakeholders is crucial. Pharmacovigilance professionals work closely with these partners to ensure a comprehensive understanding of the safety profile of the investigational drug. Pharmacovigilance in clinical research is an integral part of ensuring the safety and efficacy of medications. It involves a comprehensive approach to monitoring, reporting, and managing potential risks throughout the drug development lifecycle, from clinical trials to post-marketing surveillance. The goal is to provide healthcare professionals and consumers with up-to-date information on the safety profile of medications [12].

Pharmacovigilance Importance

Pharmacovigilance (PV) is crucial for several reasons, spanning the entire lifecycle of a pharmaceutical product. The primary goal of pharmacovigilance is to safeguard the well- being of patients. Monitoring and analyzing adverse reactions help identify potential risks associated with pharmaceutical products, allowing for timely interventions to protect patient safety [13]. Pharmacovigilance contributes to the ongoing evaluation of the risk-benefit ratio of drugs. This assessment is essential in determining whether the benefits of a medication outweigh its potential risks, helping healthcare professionals make informed decisions. Regulatory authorities require pharmaceutical companies to adhere to strict safety monitoring practices [14]. Compliance with pharmacovigilance guidelines and reporting requirements is essential for obtaining and maintaining regulatory approval for drugs. After a drug is approved and enters the market, pharmacovigilance continues through post-marketing surveillance. This real-world monitoring helps identify rare or long-term adverse effects that may not have been evident during pre-approval studies. Pharmacovigilance practices lead to updates in drug labels when new safety information emerges. This ensures that healthcare professionals and patients are informed about potential risks and adverse reactions associated with the medication. In cases where serious and unexpected side effects are identified, pharmacovigilance data can lead to regulatory decisions for drug recalls [15]. This is a critical measure to protect public health by removing potentially harmful drugs from the market. The safety profile data generated by pharmacovigilance during clinical trials provides valuable insights. This information can guide further research and development, helping companies refine their products or pursue new indications for existing drugs. Transparent and effective pharmacovigilance practices contribute to building and maintaining public trust in the healthcare system. Patients and healthcare professionals rely on accurate information about the safety of medications. Phase IV trials conducted post-marketing provide additional real-world data on drug safety and efficacy. This information is essential for understanding the long-term effects and performance of drugs in diverse patient populations and less-controlled settings [16]. The pharmacovigilance is indispensable for the continuous assessment and improvement of drug safety. It not only protects patients but also contributes to the overall success and sustainability of the pharmaceutical industry by ensuring that safe and effective medications are available to the public.

Tactical Plan of Pharmacovigilance

Pharmacovigilance in clinical trials of investigational new drugs involves a systematic and proactive approach to monitor, detect, assess, and manage the safety profile of the drug being tested [17]. The main modes of pharmacovigilance in clinical trials include the following:

Adverse Event Reporting

Investigators and other clinical trial personnel are responsible for promptly reporting any adverse events (AEs) or side effects observed in study participants. Adverse events can range from mild to severe, and the reporting should adhere to regulatory requirements and study protocols.

Safety Monitoring and Data Collection

Continuous monitoring of safety data is essential throughout the clinical trial. Data related to adverse events, serious adverse events (SAEs), and other safety parameters are systematically collected and analyzed to identify any potential safety concerns.

Regulatory Reporting

Regulatory authorities require sponsors and investigators to report serious and unexpected adverse events to them promptly. These reports, often referred to as expedited reporting, provide regulatory agencies with real- time information about the safety of the investigational drug.

Data Safety Monitoring Boards (DSMBs)

Independent DSMBs are sometimes established to monitor safety data during the course of a clinical trial. DSMBs consist of experts who review unblinded safety data at predefined intervals and provide recommendations regarding the continuation, modification, or termination of the trial based on safety considerations [18].

Risk Management Plans

Pharmacovigilance in clinical trials involves the development and implementation of risk management plans. These plans outline strategies to identify, minimize, and manage potential risks associated with the investigational drug. They may include specific safety monitoring procedures and risk mitigation measures.

Safety Database Management

Sponsors maintain safety databases that capture and organize safety-related information from clinical trials. These databases are crucial for ongoing safety evaluation and contribute to the overall pharmacovigilance efforts (Table 1).

Work-PlanDescription
Establish a Pharmacovigilance TeamIdentify and assemble a dedicated team with expertise in pharmacovigilance, including medical professionals, data analysts, regulatory affairs specialists, and communication experts.
Define Roles and ResponsibilitiesClearly define the roles and responsibilities of team members to ensure accountability and streamline workflow.
Develop Standard Operating Procedures (SOPs)Create SOPs for pharmacovigilance activities, including procedures for adverse event reporting, signal detection, risk management, and regulatory compliance.
Training and EducationConduct regular training sessions for team members and relevant stakeholders to keep them informed about pharmacovigilance guidelines, regulations, and best practices.
Implement Pharmacovigilance DatabaseUtilize a robust pharmacovigilance database to systematically collect, manage, and analyze safety data from clinical trials and post-marketing surveillance
Adverse Event Reporting ProcessEstablish a streamlined process for the collection, evaluation, and reporting of adverse events, ensuring compliance with regulatory timelines and requirements.
Signal Detection and Data AnalysisImplement tools and methodologies for signal detection and data analysis to identify potential safety concerns or emerging trends in the safety profile of drugs.
Regulatory ComplianceStay updated on regional and international pharmacovigilance regulations and ensure strict compliance with reporting obligations to regulatory agencies
Risk Management PlansDevelop and implement risk management plans for each product, outlining strategies for risk minimization and ongoing safety monitoring
Pharmacovigilance AuditsConduct internal audits to assess the effectiveness of pharmacovigilance processes, identify areas for improvement, and ensure compliance with internal procedures
Communication StrategyDevelop a clear communication strategy for internal and external stakeholders, including investigators, healthcare professionals, and the public. Ensure timely and transparent communication of safety information.
Collaboration with Key StakeholdersFoster collaboration with clinical investigators, regulatory agencies, ethics committees, and other key stakeholders to enhance pharmacovigilance efforts and share safety information
Continuous ImprovementEstablish a culture of continuous improvement by regularly reviewing and updating pharmacovigilance processes in response to emerging trends, regulatory changes, and lessons learned from ongoing activities.
Crisis Management PlanDevelop a crisis management plan to address and respond effectively to any unforeseen safety issues, including a communication strategy and contingency measures.
Periodic ReportingGenerate and submit periodic pharmacovigilance reports to regulatory authorities, summarizing safety data, risk-benefit assessments, and any actions taken to ensure product safety.
Post-Marketing SurveillanceImplement post-marketing surveillance programs to monitor the safety of drugs in real-world settings and identify any long-term or rare adverse events.
Key Performance Indicators (KPIs)Define and monitor key performance indicators to measure the effectiveness and efficiency of pharmacovigilance activities, enabling continuous evaluation and improvement.

Table 1: Sample tactical plan for Pharmacovigilance in Investigational New Drugs (IND).

Investigator Meetings and Training

Regular investigator meetings and training sessions are conducted to ensure that clinical trial personnel are well- informed about the importance of pharmacovigilance, the proper reporting procedures, and the significance of accurate and timely data collection.

Monitoring and Audits

Clinical trials are subject to monitoring visits and audits by regulatory authorities or independent organizations. These activities ensure compliance with pharmacovigilance requirements and the integrity of the safety data collected.

Safety Communication

Effective communication of safety information within the trial team, between investigators, and with regulatory agencies is crucial. Clear communication channels facilitate the prompt response to emerging safety concerns.

Continuous Benefit-Risk Assessment

Pharmacovigilance professionals engage in continuous benefit-risk assessments throughout the trial. This involves evaluating whether the anticipated benefits of the investigational drug justify its potential risks and whether any adjustments or safety measures are needed [19]. The modes of pharmacovigilance in clinical trials of investigational new drugs are multifaceted and involve a combination of active surveillance, reporting mechanisms, regulatory compliance, and ongoing safety evaluation to ensure the well-being of study participants and the validity of trial results [20]. A tactical plan for pharmacovigilance outlines specific actions and strategies to ensure the effective implementation of pharmacovigilance activities within an organization.

This tactical plan provides a framework for building and sustaining a robust pharmacovigilance system within an organization, emphasizing the importance of compliance, communication, and continuous improvement. The specifics of the plan may vary based on the organization’s size, structure, and the nature of its pharmaceutical activities [21, 22, 23, 24, 25, 26, 27, 28].

Conclusion

In the realm of investigational new drug (IND) clinical trials, the role of pharmacovigilance emerges as a cornerstone in ensuring the integrity, safety, and ethical conduct of pharmaceutical research. As novel compounds undergo rigorous evaluation, the multifaceted contributions of pharmacovigilance play a pivotal role throughout the drug development continuum. In the indispensable role of pharmacovigilance in IND clinical trials cannot be overstated. Beyond ensuring safety and compliance, it serves as a proactive force, adapting to emerging data and fortifying the ethical foundation of pharmaceutical research. As a steadfast guardian of patient well-being, pharmacovigilance contributes significantly to the ultimate goal of delivering safe, efficacious, and ethically sound treatments to the global community. We can increase the number of clinical trials and increase our participation in clinical trials with special attention to through pharmacovigilance.

References

  1. (2021) Indian Clinical Trials Market Size, Share & Trends Analysis Report, By Phase (Phase I, Phase II, Phase III, Phase IV), By Study Design (Interventional Trials, Observational Trials), By Indication, By Region, And Segment Forecasts, 2023-2030. Grand View Research, US, pp: 113.
  2. The Clinical Trials Registry- India (CTRI).
  3. The Clinical Research Profession in India.
  4. (1997) The Erice Declaration: on Communicating information drug saftey.
  5. Shuka SS, Gidwani B, Pandey R, Rao SP, Singh V, et al. (2012) Importance of Pharmacovigilance in Indian Pharmaceutical Industry. Asian J Res Pharm Sci 2(1): 4-8.
  6. Hornbuckle K, Wu HH, Fung MC (1999) Evaluation of spontaneous adverse event reports by primary reporter - A 15-year review (1983 to 1997). Therapeutic Innovation & Regulatory Science 33(4): 1117-1124.
  7. WHO (2000) Consumer reporting of ADRs.
  8. Egberts TC, Smulderes M, Konig FH, Meyboom RH, Leukfens HG (1996) Can adverse drug reactions be detected earlier? A comparison of reports by patients and professionals. BMJ 313(7056): 530-531.
  9. Norwood PK, Sampson AR (1988) A statistical methodology for postmarketing surveillance of adverse drug reaction reports. Stat Med 7(10): 1023-1030.
  10. WHO (1999) Immunization safety surveillance: Guidelines for managers of immunization programmes on reporting and investigating adverse events following immunization. Immunization Focus: WHO Regional Office for the Western Pacific, World Health Organization, Manila, Philippines.
  11. WHO (1997) Surveillance of adverse events following immunization: Field guide form managers of immunization programmes. Global programme for vaccines and immunization: Expanded Programme on Immunization. World Health Organization, Geneva, Switzerland.
  12. Simonsen L, Kane A, Lloyd J, Zaffran M, Kane M (1999) Unsafe injections in the developing world and transmission of bloodborne pathogens: a review. Bull World Health Organ 77(10): 789-800.
  13. Strom BL (2012) Overview of automated databases in pharmacoepidemiology. In: Stephen EK, et al. (Eds.), Pharmacoepidemiology Chichester. John Wiley & Sons, UK, pp: 219-222.
  14. Ducuing FB, Riviere F, Aarum S, Garcia JL (2010) European medicines agency support mechanisms fostering orphan drug development. Drug News Perspect 23(1): 71-81.
  15. Giezen TJ, Teeuwisse AKM, Straus SMJM, Egberts TCG, Blackburn S, et al. (2009) Evaluation of post- authorization safety studies in the first cohort of EU risk management plans at time of regulatory approval. Drug Saf 32(12): 1175-1187.
  16. Herret E, Thomas SL, Schoonen WM, Smeeth L, Hall AJ (2010) Validation and validity of diagnoses in the general practice research database: a systematic review. J Clin Pharmacol 69(1): 4-14.
  17. Abenhaim L, Moride Y, Brenot F, Rich S, Benichou J, et al. (1996) Appetite-suppressant drugs and the risk of primary pulmonary hypertension. N Engl J Med 335(9): 609-616.
  18. Kaufman DW, Rosenberg L, Mitchell AA (2001) Signal generation and clarification: Use of case-control data. Pharmacoepidemiol Drug Saf 10(3): 197-203.
  19. Stefano F, Tokars J (2010) H1N1 vaccine safety monitoring: Beyond background rates. Lancet 375(9721): 1146-1147.
  20. Chen RT, Stefano FD, Davis RL, Jackson LA, Thompson RS, et al. (2000) The vaccine safety datalink: Immunization research in health maintenance organizations in the USA. Bull World Health Organ 78(2): 186-194.
  21. Stichele RHV, Elseviers MM, Ferech M, Blot S (2004) European Surveillance of Antimicrobial Consumption (ESAC): Data collection performance and methodological approach. Br J Clin Pharmacol 58(4): 419-28.
  22. Martirosyan L, Voorham J, Haaijer-Ruskamp FM, Braspenning J, Wolffenbuttel BHR, et al. (2010) Systematic literature review: Prescribing indicators related to type 2 diabetes mellitus and cardiovascular risk management. Pharmacoepidemiol Drug Saf 19(4): 319-334.
  23. Laue NC, Schwappach DLB, Koeck CM (2003) The epidemiology of preventable adverse drug events: A review of literature. Wien Klin Wochenschr 115(12): 407-415.
  24. Aneesh TP, Sekhar SM, Jose A, Chandran L, Zachariaha SM, et al. (2009) Pharmacogenomics: The Right Drug to the Right Person. J Clin Med Res 1(4): 191-194.
  25. Brockmöller J, Tzvetkov MV (2008) Pharmacogenetics: data, concepts and tools to improve drug discovery and drug treatment. Eur J Clin Pharmacol 64(2): 133-157.
  26. Somers GS (1962) Thalidomide and congenital abnormalities. Lancet 1(7235): 912-913.
  27. Bégaud B, Chaslerie A, Haramburu F (1994) Organization and results of drug vigilance in France. Rev Epidemiol Sante Publique 42(5): 416-423.
  28. WHO (2002) The Importance of Pharmacovigilance, Safety Monitoring of medicinal products.
More from this journal

Cite this article

BibTeX
APA
RIS
@article{mohammad2024,
  title   = {The Role of Pharmacovigilance in Investigational New Drug (IND) Clinical Trials},
  author  = {Mohammad Nadeem Khan},
  journal = {Advances in Pharmacology & Clinical Trials},
  year    = {2024},
  volume  = {9},
  number  = {1},
  doi     = {10.23880/apct-16000233}
}
Mohammad Nadeem Khan (2024). The Role of Pharmacovigilance in Investigational New Drug (IND) Clinical Trials. Advances in Pharmacology & Clinical Trials, 9(1). https://doi.org/10.23880/apct-16000233
TY  - JOUR
TI  - The Role of Pharmacovigilance in Investigational New Drug (IND) Clinical Trials
AU  - Mohammad Nadeem Khan
JO  - Advances in Pharmacology & Clinical Trials
PY  - 2024
VL  - 9
IS  - 1
DO  - 10.23880/apct-16000233
ER  -